Gilead Sciences has earmarked $2bn to take a stake in Belgium's Galapagos and buy into its filgotinib drug candidate for rheumatoid arthritis.

The US FDA has approved Merck & Co's Bridion to reverse the effects of neuromuscular blockade induced by muscle relaxants used during surgery.

ArchiMed, Europe's first independent private equity healthcare specialist, has acquired majority control of Deallus Consulting.